Company / Book Value per Share
CRISPR Therapeutics AG Book Value per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Book Value per Share
$20.041
FY2025
5-year range
$20.041 / $31.166
FY2021-FY2025
Trend
-11.1%
vs FY2024
Sector context
#28 of 209
Health Care
What the data says
CRISPR Therapeutics AG's book value per share of $20.041 is higher than 87% of companies in the Health Care sector (FY2025). Book Value per Share has declined for 4 consecutive years, from $31.166 in FY2021 to $20.041 in FY2025.
Based on SEC 10-K filings.
$20.041 in FY2025 with a 5-year CAGR of -2.3%. Top quartile in the Health Care sector.
Declined from $23.522 to $20.041 over the past 2 years.
Health Care sector context is included.
Book Value per Share over time
Growth rates
- 3-Year CAGR
- -5.7%
- 5-Year CAGR
- -2.3%
- 10-Year CAGR
- -
Sector benchmark
-89.4% below sector average
Key checks
Key Insights
- CRISPR Therapeutics AG's book value per share has declined for 4 consecutive years.
- 5-year CAGR of -2.3%, indicating a declining trend.
- In FY2025, book value per share decreased 11.1% year-over-year.
- Ranks #28 out of 209 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Book Value per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $20.041 | -11.1% |
| FY2024 | $22.534 | -4.2% |
| FY2023 | $23.522 | -1.5% |
| FY2022 | $23.888 | -23.4% |
| FY2021 | $31.166 | +38.4% |
| FY2020 | $22.516 | +24.3% |
| FY2019 | $18.117 | +291.5% |
| FY2018 | $4.627 | -21.1% |
| FY2017 | $5.862 | -86.1% |
| FY2016 | $42.121 | +828.5% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026